435 related articles for article (PubMed ID: 15841378)
41. Immune expression and inhibition of heat shock protein 90 in uveal melanoma.
Faingold D; Marshall JC; Antecka E; Di Cesare S; Odashiro AN; Bakalian S; Fernandes BF; Burnier MN
Clin Cancer Res; 2008 Feb; 14(3):847-55. PubMed ID: 18245548
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.
Smith NF; Hayes A; Nutley BP; Raynaud FI; Workman P
Cancer Chemother Pharmacol; 2004 Dec; 54(6):475-86. PubMed ID: 15526201
[TBL] [Abstract][Full Text] [Related]
43. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
44. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
[TBL] [Abstract][Full Text] [Related]
45. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
Yun BG; Matts RL
Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741
[TBL] [Abstract][Full Text] [Related]
46. Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.
Hardcastle A; Boxall K; Richards J; Tomlin P; Sharp S; Clarke P; Workman P; Aherne W
Assay Drug Dev Technol; 2005 Jun; 3(3):273-85. PubMed ID: 15971989
[TBL] [Abstract][Full Text] [Related]
47. Geldanamycin and its anti-cancer activities.
Fukuyo Y; Hunt CR; Horikoshi N
Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
[TBL] [Abstract][Full Text] [Related]
48. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma.
Schmitt E; Maingret L; Puig PE; Rerole AL; Ghiringhelli F; Hammann A; Solary E; Kroemer G; Garrido C
Cancer Res; 2006 Apr; 66(8):4191-7. PubMed ID: 16618741
[TBL] [Abstract][Full Text] [Related]
49. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
Neckers L
Clin Cancer Res; 2002 May; 8(5):962-6. PubMed ID: 12006507
[No Abstract] [Full Text] [Related]
50. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
[TBL] [Abstract][Full Text] [Related]
51. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.
Gray PJ; Stevenson MA; Calderwood SK
Cancer Res; 2007 Dec; 67(24):11942-50. PubMed ID: 18089825
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of heat shock protein 90 attenuates post‑angioplasty intimal hyperplasia.
Kassem MM; Muqri F; Dacosta M; Bruch D; Gahtan V; Maier KG
Mol Med Rep; 2020 Apr; 21(4):1959-1964. PubMed ID: 32319637
[TBL] [Abstract][Full Text] [Related]
53. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.
Newcomb EW; Lukyanov Y; Schnee T; Esencay M; Fischer I; Hong D; Shao Y; Zagzag D
Anticancer Drugs; 2007 Sep; 18(8):875-82. PubMed ID: 17667592
[TBL] [Abstract][Full Text] [Related]
54. Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells.
Tsui KH; Feng TH; Hsieh WC; Chang PL; Juang HH
Acta Pharmacol Sin; 2008 Nov; 29(11):1334-41. PubMed ID: 18954528
[TBL] [Abstract][Full Text] [Related]
55. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
[TBL] [Abstract][Full Text] [Related]
56. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
57. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
58. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Bonvini P; An WG; Rosolen A; Nguyen P; Trepel J; Garcia de Herreros A; Dunach M; Neckers LM
Cancer Res; 2001 Feb; 61(4):1671-7. PubMed ID: 11245482
[TBL] [Abstract][Full Text] [Related]
59. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
60. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
